推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733,021-33632861

chinasupport@letpub.com

登录 注册 新注册优惠

OncoImmunology

2023年12月最新中科院分区表数据已经更新,欢迎查询! 如果您对期刊系统有任何需求或者问题,欢迎点击此处反馈给我们。

按期刊名首写字母查看 ONCOIMMUNOLOGY最新评论:2023.8.1投稿,2个月给了第一轮大修意见;1个月修回后,返回原始审稿人那里继续不设时间限制让他们审稿,1个半月后第二轮大修意... (2024-03-05)


期刊名:   ISSN:   研究方向:   影响因子: -   SCI收录:
大类学科:   小类学科:   中科院分区:   是否OA期刊:   结果排序:

同行评审状态查询 Manuscript Number * Last Name * First Name * 出版社 * 查 询 重 置

按研究方向查看:


OncoImmunology期刊基本信息Hello,您是该期刊的第47393位访客

基本信息 登录收藏
期刊名字OncoImmunologyOncoImmunology

ONCOIMMUNOLOGY
(此期刊被最新的JCR期刊SCIE收录)

LetPub评分
7.8
54人评分
我要评分

声誉
8.8

影响力
6.8

速度
9.4

期刊ISSN2162-4011
微信扫码收藏此期刊
E-ISSN2162-402X
2022-2023最新影响因子
(数据来源于搜索引擎)
7.2 点击查看影响因子趋势图
实时影响因子 截止2023年12月27日:5.492
2022-2023自引率2.80%点击查看自引率趋势图
五年影响因子7.6
h-index 58
CiteScore
CiteScoreSJRSNIPCiteScore排名
12.502.0031.083
学科分区排名百分位
大类:Medicine
小类:Oncology
Q137 / 366
大类:Medicine
小类:Immunology and Allergy
Q127 / 211
大类:Medicine
小类:Immunology
Q131 / 217

期刊简介
Tumor immunology deals with the natural or therapy-induced recognition of cancers, as well as with the intricate interplay between oncogenesis, inflammation and immunosurveillance. We now create a new, high-profile journal, OncoImmunology, that specifically deals with tumor immunology. Recent progress has allowed for the first clinical demonstration (and FDA approval) of anticancer immunotherapies. There is also an ever growing suspicion that - unexpectedly - many of the currently used chemotherapeutic agents depend in their efficacy on the active contribution of immune effectors. To use a drastic metaphor, oncologists who applied successful chemotherapeutic (or radiotherapeutic) regimens have taken advantage of the immune system's capacity to recognize tumor-specific or tumor-associated antigens and to control cancer (stem) cell growth, without being aware of the invisible helping hands. As a result, immunological biomarkers are becoming ever more important to determine the prognosis of cancers and to predict the efficacy of chemotherapies. There is also a strong rationale in favor of combining conventional anticancer therapies with immunotherapies.
OncoImmunology will accept high-profile submissions in the fundamental, translational and clinical areas of tumor immunology. Submissions dealing with solid or hematological cancers, inflammation, innate and acquired immune responses will be welcome.
期刊官方网站http://www.tandfonline.com/loi/koni20
期刊投稿网址https://www.editorialmanager.com/ONCOIMM
期刊语言要求经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足OncoImmunology的语言要求,还能让OncoImmunology编辑和审稿人得到更好的审稿体验,让稿件最大限度地被OncoImmunology编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢
提交文稿
是否OA开放访问No
通讯方式530 WALNUT STREET, STE 850, PHILADELPHIA, USA, PA, 19106
出版商Landes Bioscience
涉及的研究方向ONCOLOGY-IMMUNOLOGY
出版国家或地区UNITED STATES
出版语言English
出版周期
出版年份0
年文章数 174点击查看年文章数趋势图
Gold OA文章占比99.69%
研究类文章占比:
文章 ÷(文章 + 综述)
94.25%
WOS期刊SCI分区
2022-2023年最新版
WOS分区等级:1区

按学科分区JIF分区JIF排名JIF百分位
学科:IMMUNOLOGY
类别:SCIE
Q137/161
学科:ONCOLOGY
类别:SCIE
Q147/241
中科院《国际期刊预警
名单(试行)》名单
2024年02月发布的2024版:不在预警名单中

2023年01月发布的2023版:不在预警名单中

2021年12月发布的2021版:不在预警名单中

2020年12月发布的2020版:不在预警名单中
中科院SCI期刊分区
2023年12月最新升级版
点击查看中科院SCI期刊分区趋势图
大类学科小类学科Top期刊综述期刊
医学 1区2区3区
IMMUNOLOGY
免疫学
4区4区2区
ONCOLOGY
肿瘤学
2区3区2区
中科院SCI期刊分区
2022年12月升级版
大类学科小类学科Top期刊综述期刊
医学 1区2区2区
IMMUNOLOGY
免疫学
4区2区2区
ONCOLOGY
肿瘤学
3区1区3区
中科院SCI期刊分区
2021年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学 2区2区3区
IMMUNOLOGY
免疫学
1区2区2区
ONCOLOGY
肿瘤学
4区3区2区
SCI期刊收录coverage Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE)
Scopus (CiteScore)
Directory of Open Access Journals (DOAJ)
PubMed Central (PMC)链接http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2162-4011%5BISSN%5D
平均审稿速度网友分享经验:
24 Weeks
平均录用比例网友分享经验:
LetPub助力发表经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)后论文在OncoImmunology顺利发表。
快看看作者怎么说吧:服务好评 论文致谢
期刊常用信息链接
同领域相关期刊 OncoImmunology期刊近年CiteScore指标趋势图
该杂志的自引率趋势图 OncoImmunology中科院SCI期刊分区趋势图
该杂志的年文章数趋势图 同领域作者分享投稿经验
OncoImmunology上中国学者近期发表的论文  
  • 同领域相关期刊
  • 期刊CiteScore趋势图
  • 期刊自引率趋势图
  • 中科院SCI期刊分区趋势图
  • 年文章数趋势图
  • 该期刊中国学者近期发表论文
  • 中科院SCI期刊分区相关期刊
  • 同类著名期刊名称 h-index CiteScore
    Science Immunology030.20
    Cancer Immunology Research6218.80
    Journal of Allergy and Clinical Immunology-In Practice4010.30
    npj Vaccines811.40
    HLA933.00
    Immunity & Ageing3810.90
    OncoImmunology4912.50
    ALLERGOLOGY INTERNATIONAL4511.80
    Immune Network118.80
    World Allergy Organization Journal297.30
    中科院SCI期刊分区同大类学科的热搜期刊 浏览次数
    MEDICINE599763
    BIOMATERIALS512633
    BIOMEDICINE & PHARMACOTHERAPY461747
    Journal of Materials Chemistry B458348
    Frontiers in Pharmacology448129
    Frontiers in Immunology419091
    JOURNAL OF ETHNOPHARMACOLOGY403508
    COLLOIDS AND SURFACES B-BIOINTERFACES403035
    Frontiers in Oncology382426
    Acta Biomaterialia374549
  •  

    OncoImmunology OncoImmunology
    我来预测明年:
    稳步上升 表现平稳 逐渐下降  刷新
  •  

     
  •  

     
  •  

     
  • 中国学者近期发表的论文
    1.M2 macrophage-derived exosomes suppress tumor intrinsic immunogenicity to confer immunotherapy resistance

    Author: Zheng, Naisheng; Wang, Tingting; Luo, Qin; Liu, Yi; Yang, Junyao; Zhou, Yunlan; Xie, Guohua; Ma, Yanhui; Yuan, Xiangliang; Shen, Lisong
    Journal: ONCOIMMUNOLOGY. 2023; Vol. 12, Issue 1, pp. -. DOI: 10.1080/2162402X.2023.2210959
        PubMed      DOI
    2.Expression of OLR1 gene on tumor-associated macrophages of head and neck squamous cell carcinoma, and its correlation with clinical outcome

    Author: Zhang, Peng; Zhao, Yan; Xia, Xin; Mei, Song; Huang, Yixuan; Zhu, Yingying; Yu, Shuting; Chen, Xingming
    Journal: ONCOIMMUNOLOGY. 2023; Vol. 12, Issue 1, pp. -. DOI: 10.1080/2162402X.2023.2203073
        PubMed      DOI
    3.Altered phenotypic and metabolic characteristics of FOXP3(+)CD3(+)CD56(+) natural killer T (NKT)-like cells in human malignant pleural effusion

    Author: Wang, Zi-Hao; Zhang, Pei; Peng, Wen-Bei; Ye, Lin-Lin; Xiang, Xuan; Wei, Xiao-Shan; Niu, Yi-Ran; Zhang, Si-Yu; Xue, Qian-Qian; Wang, Hao-Lei; Zhou, Qiong
    Journal: ONCOIMMUNOLOGY. 2023; Vol. 12, Issue 1, pp. -. DOI: 10.1080/2162402X.2022.2160558
        PubMed      DOI
    4.Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer

    Author: Wang, Fulong; Lu, Shixun; Cao, Di; Qian, Juanjuan; Li, Cong; Zhang, Rongxin; Wang, Feng; Wu, Miaoqing; Liu, Yifan; Pan, Zhizhong; Wu, Xiaojun; Lu, Zhenhai; Ding, Peirong; Li, Liren; Lin, Junzhong; Catteau, Aurelie; Galon, Jerome; Chen, Gong
    Journal: ONCOIMMUNOLOGY. 2023; Vol. 12, Issue 1, pp. -. DOI: 10.1080/2162402X.2022.2161167
        PubMed      DOI
    5.CARD9 deficiency promotes pancreatic cancer growth by blocking dendritic cell maturation via SLC6A8-mediated creatine transport

    Author: Tian, Cheng; Yuan, Huimin; Lu, Yi; He, Henghui; Li, Qing; Li, Senlin; Yang, Jian; Wang, Mengheng; Xu, Ruochen; Liu, Qian; Xiang, Ming
    Journal: ONCOIMMUNOLOGY. 2023; Vol. 12, Issue 1, pp. -. DOI: 10.1080/2162402X.2023.2204015
        PubMed      DOI
    6.Gankyrin-mediated interaction between cancer cells and tumor-associated macrophages facilitates prostate cancer progression and androgen deprivation therapy resistance

    Author: Peng, Guang; Wang, Chao; Wang, Hongru; Qu, Min; Dong, Keqin; Yu, Yongwei; Jiang, Yuquan; Gan, Sishun; Gao, Xu
    Journal: ONCOIMMUNOLOGY. 2023; Vol. 12, Issue 1, pp. -. DOI: 10.1080/2162402X.2023.2173422
        PubMed      DOI
    7.Suppression of prostate cancer and amelioration of the immunosuppressive tumor microenvironment through selective immunoproteasome inhibition

    Author: Koerner, Julia; Horvath, Dennis; Oliveri, Franziska; Li, Jun; Basler, Michael
    Journal: ONCOIMMUNOLOGY. 2023; Vol. 12, Issue 1, pp. -. DOI: 10.1080/2162402X.2022.2156091
        PubMed      DOI
    8.Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles

    Author: Deng, Jun; Ke, Hui
    Journal: ONCOIMMUNOLOGY. 2023; Vol. 12, Issue 1, pp. -. DOI: 10.1080/2162402X.2022.2152635
        PubMed      DOI
    9.Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort.

    Author: Wang Q1,2, Gregg JR3, Gu J1, Ye Y1, Chang DW1, Davis JW3, Thompson TC4, Kim J3, Logothetis CJ4, Wu X1.
    Journal: Oncoimmunology. 2018 Oct 29;8(1):e1483303. doi: 10.1080/2162402X.2018.1483303. eCollection 2019.
        PubMed      DOI
    10.DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells.

    Author: Zhao R1,2,3, Cheng L1,2, Jiang Z1,2, Wei X1,2, Li B1,2, Wu Q1,2, Wang S1,2, Lin S1,2, Long Y1,2, Zhang X4, Wu Y4, Du X5, Pei D1,2, Liu P6, Li Y7, Cui S8, Yao Y1,2, Li P1,2,8.
    Journal: Oncoimmunology. 2018 Nov 2;8(1):e1509173. doi: 10.1080/2162402X.2018.1509173. eCollection 2019.
        PubMed      DOI
  • 同大类学科的其他著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144642.90
    LANCET700133.20
    NEW ENGLAND JOURNAL OF MEDICINE933134.40
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION62245.40
    NATURE REVIEWS DRUG DISCOVERY289123.80
    BMJ-British Medical Journal015.30
    BMJ-British Medical Journal015.30
    NATURE REVIEWS IMMUNOLOGY35183.00
    NATURE MEDICINE497107.50
    Nature Reviews Disease Primers4860.90
    同分区等级的其他期刊名称 h-index CiteScore
    Living Reviews in Relativity065.50
    Living Reviews in Relativity7565.50
    JOURNAL OF TRAVEL MEDICINE5119.60
    Military Medical Research030.10
    Advanced Composites and Hybrid Materials016.90
    INTERNATIONAL JOURNAL OF COMPUTER VISION17222.50
    Eurosurveillance9027.70
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE715.70
    Small Structures00.00
    Trends in Chemistry032.10


以上SCI期刊相关数据和信息来源于网络,仅供参考。
投稿状态统计: 我要评分:

    同领域作者分享投稿经验:共2条 (包含回复)

我来分享

    联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

    © 2010-2024 中国: LetPub上海分公司    网站备案号:沪ICP备10217908号-1    沪公网安备号:31010402006960

    增值电信业务经营许可证:沪B2-20211595

    礼翰商务信息咨询(上海)有限公司      办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室

    United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451